About kaleo
kaleo is a company based in Richmond (United States) founded in 2005 was acquired by Marathon Asset Management in November 2021. The company has 220 employees as of December 31, 2020. kaleo offers products and services including Aerio™ Auto-Injector Platform. kaleo operates in a competitive market with competitors including PharmaJet, Arecor, Suono Bio, Renovis and Ensysce, among others.
- Headquarter Richmond, United States
- Employees 220 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kaleo, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$150 M (USD), Debt – Conventional
Apr 07, 2014
-
Investors
Hercules Capital
& 2 more
-
Employee Count
220
as on Dec 31, 2020
-
Acquired by
Marathon Asset Management
(Nov 29, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of kaleo
kaleo offers a comprehensive portfolio of products and services, including Aerio™ Auto-Injector Platform.
Delivers medications via auto-injector for emergency patient care.
Funding Insights of kaleo
Investors in kaleo
kaleo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Marathon Asset Management and PDL BioPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical company undergoing dissolution and asset distribution processes.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Diversified investment management services are provided across asset classes.
|
Locked | Locked | Locked |
Investor details for kaleo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by kaleo
Investment portfolio details for kaleo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - kaleo
Detailed financials for kaleo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kaleo Comparisons
Peer comparison for kaleo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of kaleo
kaleo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PharmaJet, Arecor, Suono Bio, Renovis and Ensysce, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
|
|
| Locked | Locked | Locked |
Drugs for neurological diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
Provider of a proprietary platform for gene therapy
|
Detailed competitors of kaleo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kaleo
Complete news archive for kaleo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about kaleo
kaleo was founded in 2005 and raised its 1st funding round 7 years after it was founded.
kaleo is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.
Spencer Williamson is the current CEO of kaleo.
As of Dec 31, 2020, the latest employee count at kaleo is 220.
Kaleo was founded in 2005 and is based in Richmond, United States. Auto-injector based pharmaceutical products are developed for use during medical emergencies, such as opioid overdose and allergic reactions. These products, including naloxone HCl injection and epinephrine autoinjector, are administered by patients or caretakers. Operations focus on the pharmaceutical sector, with emphasis on emergency response solutions.
kaleo's top competitors include Oxular, PharmaJet and Splice Bio.
kaleo offers Aerio™ Auto-Injector Platform.
kaleo has 3 investors. Key investors include Hercules Capital, Marathon Asset Management, and PDL BioPharma.